CIK 0000906709
- Non-accelerated filer
- Smaller reporting company
NEKTAR THERAPEUTICS
Sign in to watch- Ticker
- NKTR
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 943134940
- Phone
- +1 415-482-5300
- Business address
- 455 MISSION BAY BOULEVARD SOUTH, SAN FRANCISCO, CA, 94158
- Former names
- INHALE THERAPEUTIC SYSTEMS INC, INHALE THERAPEUTIC SYSTEMS
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2016-12-13 | Doberstein Stephen K SVP & Chief Scientific Officer | Grant or award | +17,500 | 35,765 | ||
| 2016-12-13 | Doberstein Stephen K SVP & Chief Scientific Officer | Grant or award · Stock Option | +43,750 | 43,750 | ||
| 2016-12-07 | ROBIN HOWARD W President & CEO | Exercise or conversion | +87,500 | $4.65 | $407K | 210,408 |
| 2016-12-07 | ROBIN HOWARD W President & CEO | Sale | −87,500 | $12.24 | $1.1M | 122,908 |
| 2016-12-07 | ROBIN HOWARD W President & CEO | Exercise or conversion · Stock Option | −87,500 | 175,000 | ||
| 2016-11-17 | ROBIN HOWARD W President & CEO | Exercise or conversion | +87,500 | $4.65 | $407K | 210,408 |
| 2016-11-17 | ROBIN HOWARD W President & CEO | Sale | −87,500 | $13.87 | $1.2M | 122,908 |
| 2016-11-17 | ROBIN HOWARD W President & CEO | Exercise or conversion · Stock Option | −87,500 | 262,500 | ||
| 2016-11-16 | Thomsen Jillian B. SVP & Chief Accounting Officer | Sale | −1,986 | $13.96 | $28K | 42,102 |
| 2016-11-16 | ROBIN HOWARD W President & CEO | Sale | −5,958 | $13.96 | $83K | 122,908 |
| 2016-11-16 | Nicholson John SVP & Chief Operating Officer | Sale | −1,654 | $13.96 | $23K | 120,326 |
| 2016-11-16 | Labrucherie Gil M SVP & Chief Financial Officer | Sale | −1,654 | $13.96 | $23K | 51,129 |
| 2016-11-16 | Hora Maninder SVP Pharma Dev & Mfg Ops | Sale | −1,654 | $13.96 | $23K | 50,343 |
| 2016-11-16 | Gergel Ivan P. SVP & Chief Medical Officer | Sale | −848 | $13.96 | $12K | 26,479 |
| 2016-11-16 | Doberstein Stephen K SVP & Chief Scientific Officer | Sale | −670 | $13.96 | $9K | 18,265 |
| 2016-10-24 | GREER R SCOTT Director | Purchase | +15,000 | $13.50 | $203K | 121,333 |
| 2016-10-04 | ROBIN HOWARD W President & CEO | Exercise or conversion | +87,500 | $4.65 | $407K | 216,366 |
| 2016-10-04 | ROBIN HOWARD W President & CEO | Sale | −87,500 | $17.06 | $1.5M | 128,866 |
| 2016-10-04 | ROBIN HOWARD W President & CEO | Exercise or conversion · Stock Option | −87,500 | 350,000 | ||
| 2016-09-23 | WHITFIELD ROY A Director | Exercise or conversion | +15,000 | $5.15 | $77K | 53,000 |
Page 47 of 55 · 1,088 trades